Anticancer Drug Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

Table of Content

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations

2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Drug Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Global Anticancer Drug Market Outlook
4.1. Market Size & Forecast
4.1.1. By Value
4.2. Market Share & Forecast
4.2.1. By Indication (Breast Cancer, Blood Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer, Others)
4.2.2. By Drug (Cytotoxics, Hormonal Therapy, Targeted Therapy, Others)
4.2.3. By Route of Administration (Oral, Parenteral, Others)
4.2.4. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
4.2.5. By Region
4.2.6. By Company (2023)
4.3. Market Map
4.3.1. By Indication
4.3.2. By Drug
4.3.3. By Route of Administration
4.3.4. By End User
4.3.5. By Region

5. Asia Pacific Anticancer Drug Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Indication
5.2.2. By Drug
5.2.3. By Route of Administration
5.2.4. By End User
5.2.5. By Country
5.3. Asia Pacific: Country Analysis
5.3.1. China Anticancer Drug Market Outlook
5.3.1.1. Market Size & Forecast
5.3.1.1.1. By Value
5.3.1.2. Market Share & Forecast
5.3.1.2.1. By Indication
5.3.1.2.2. By Drug
5.3.1.2.3. By Route of Administration
5.3.1.2.4. By End User
5.3.2. India Anticancer Drug Market Outlook
5.3.2.1. Market Size & Forecast
5.3.2.1.1. By Value
5.3.2.2. Market Share & Forecast
5.3.2.2.1. By Indication
5.3.2.2.2. By Drug
5.3.2.2.3. By Route of Administration
5.3.2.2.4. By End User
5.3.3. Australia Anticancer Drug Market Outlook
5.3.3.1. Market Size & Forecast
5.3.3.1.1. By Value
5.3.3.2. Market Share & Forecast
5.3.3.2.1. By Indication
5.3.3.2.2. By Drug
5.3.3.2.3. By Route of Administration
5.3.3.2.4. By End User
5.3.4. Japan Anticancer Drug Market Outlook
5.3.4.1. Market Size & Forecast
5.3.4.1.1. By Value
5.3.4.2. Market Share & Forecast
5.3.4.2.1. By Indication
5.3.4.2.2. By Drug
5.3.4.2.3. By Route of Administration
5.3.4.2.4. By End User
5.3.5. South Korea Anticancer Drug Market Outlook
5.3.5.1. Market Size & Forecast
5.3.5.1.1. By Value
5.3.5.2. Market Share & Forecast
5.3.5.2.1. By Indication
5.3.5.2.2. By Drug
5.3.5.2.3. By Route of Administration
5.3.5.2.4. By End User

6. Europe Anticancer Drug Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Indication
6.2.2. By Drug
6.2.3. By Route of Administration
6.2.4. By End User
6.2.5. By Country
6.3. Europe: Country Analysis
6.3.1. France Anticancer Drug Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Indication
6.3.1.2.2. By Drug
6.3.1.2.3. By Route of Administration
6.3.1.2.4. By End User
6.3.2. Germany Anticancer Drug Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Indication
6.3.2.2.2. By Drug
6.3.2.2.3. By Route of Administration
6.3.2.2.4. By End User
6.3.3. Spain Anticancer Drug Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Indication
6.3.3.2.2. By Drug
6.3.3.2.3. By Route of Administration
6.3.3.2.4. By End User
6.3.4. Italy Anticancer Drug Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Indication
6.3.4.2.2. By Drug
6.3.4.2.3. By Route of Administration
6.3.4.2.4. By End User
6.3.5. United Kingdom Anticancer Drug Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Indication
6.3.5.2.2. By Drug
6.3.5.2.3. By Route of Administration
6.3.5.2.4. By End User

7. North America Anticancer Drug Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Indication
7.2.2. By Drug
7.2.3. By Route of Administration
7.2.4. By End User
7.2.5. By Country
7.3. North America: Country Analysis
7.3.1. United States Anticancer Drug Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Indication
7.3.1.2.2. By Drug
7.3.1.2.3. By Route of Administration
7.3.1.2.4. By End User
7.3.2. Mexico Anticancer Drug Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Indication
7.3.2.2.2. By Drug
7.3.2.2.3. By Route of Administration
7.3.2.2.4. By End User
7.3.3. Canada Anticancer Drug Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Indication
7.3.3.2.2. By Drug
7.3.3.2.3. By Route of Administration
7.3.3.2.4. By End User
8. South America Anticancer Drug Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Indication
8.2.2. By Drug
8.2.3. By Route of Administration
8.2.4. By End User
8.2.5. By Country
8.3. South America: Country Analysis
8.3.1. Brazil Anticancer Drug Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Indication
8.3.1.2.2. By Drug
8.3.1.2.3. By Route of Administration
8.3.1.2.4. By End User
8.3.2. Argentina Anticancer Drug Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Indication
8.3.2.2.2. By Drug
8.3.2.2.3. By Route of Administration
8.3.2.2.4. By End User
8.3.3. Colombia Anticancer Drug Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Indication
8.3.3.2.2. By Drug
8.3.3.2.3. By Route of Administration
8.3.3.2.4. By End User
9. Middle East and Africa Anticancer Drug Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Indication
9.2.2. By Drug
9.2.3. By Route of Administration
9.2.4. By End User
9.2.5. By Country
9.3. MEA: Country Analysis
9.3.1. South Africa Anticancer Drug Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Indication
9.3.1.2.2. By Drug
9.3.1.2.3. By Route of Administration
9.3.1.2.4. By End User
9.3.2. Saudi Arabia Anticancer Drug Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Indication
9.3.2.2.2. By Drug
9.3.2.2.3. By Route of Administration
9.3.2.2.4. By End User
9.3.3. UAE Anticancer Drug Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Indication
9.3.3.2.2. By Drug
9.3.3.2.3. By Route of Administration
9.3.3.2.4. By End User

10. Market Dynamics
10.1. Drivers
10.2. Challenges

11. Market Trends & Developments
11.1. Recent Developments
11.2. Product Launches
11.3. Mergers & Acquisitions

12. Global Anticancer Drug Market: SWOT Analysis

13. Porter’s Five Forces Analysis
13.1. Competition in the Drug
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Product

14. Competitive Landscape
14.1. F. Hoffmann-La Roche Ltd
14.1.1. Company Snapshot
14.1.2. Product & Services
14.1.3. Financials (In case of listed)
14.1.4. Recent Developments
14.1.5. SWOT Analysis
14.2. Genentech, Inc.
14.3. Novartis AG
14.4. Pfizer Inc.
14.5. Bristol-Myers Squibb Company
14.6. GlaxoSmithKline plc.
14.7. Eli Lilly and Company
14.8. AstraZeneca plz
14.9. Sanofi LLC
14.10.Bayer AG

15. Strategic Recommendations

16. About Us & Disclaimer